中国P站

Kidney transplantation; Acute rejection; Urinary biomarkers; Exosomes; MicroRNAs; Non-invasive diagnostics; Allograft monitoring; Transplant immunology; RNA profiling; Precision medicine

Introduction

Acute rejection remains a critical threat to the long-term success of kidney transplantation, often leading to graft dysfunction and eventual loss [1-5]. Timely diagnosis is essential, yet the current gold standard—kidney allograft biopsy—is invasive, carries procedural risks, and may not be feasible for frequent monitoring. This limitation has intensified the search for non-invasive biomarkers that can detect rejection early and accurately. Among emerging strategies, urinary exosomal microRNAs (miRNAs) have shown great promise due to their stability, tissue specificity, and capacity to reflect underlying immunologic changes within the graft. This study explores the utility of urinary exosomal miRNAs as a novel, non-invasive tool for diagnosing acute rejection in kidney transplant recipients [6-10].

Discussion

Exosomes are small extracellular vesicles (30–150 nm) secreted by cells into biological fluids, including urine. They carry various molecular cargo—proteins, lipids, and nucleic acids—that represent the physiological or pathological state of their tissue of origin. In kidney transplantation, urinary exosomes are believed to originate directly from renal tubular cells and infiltrating immune cells, making them ideal for real-time allograft surveillance.

MicroRNAs are short (≈22 nucleotide), non-coding RNA molecules that regulate gene expression post-transcriptionally. Specific miRNAs have been implicated in inflammatory processes, immune activation, and tissue injury. Studies have identified several candidate miRNAs—such as miR-21, miR-155, miR-210, and miR-200b—whose expression is significantly altered during episodes of T cell-mediated and antibody-mediated rejection.

In this multicenter study involving 124 kidney transplant recipients, urinary exosomes were isolated using ultracentrifugation, and miRNA profiling was performed via next-generation sequencing. Patients were categorized based on biopsy results into groups with biopsy-proven acute rejection (AR), stable graft function, and non-rejection injury. A panel of five miRNAs (including miR-21 and miR-155) was found to be significantly upregulated in AR cases compared to controls, with area under the curve (AUC) values > 0.85 for each in ROC analysis, indicating high diagnostic accuracy.

One of the major advantages of urinary miRNA-based diagnostics is the non-invasive nature of sample collection, allowing for longitudinal monitoring and early intervention. These biomarkers were detectable weeks before clinical signs (e.g., rising serum creatinine), offering a potential window of opportunity for preemptive treatment.

Mechanistically, miR-155 is known to modulate T-cell activation and cytokine signaling, while miR-21 plays a role in fibrosis and immune regulation. These biological insights strengthen the rationale for their use not only as diagnostic tools but potentially as therapeutic targets.

In terms of clinical translation, challenges remain, including standardization of exosome isolation, inter-individual variability, and integration into existing workflows. Nevertheless, the reproducibility of results across different patient populations and the stability of miRNAs in urine offer a clear advantage over serum-based or gene expression-based tests that are more invasive or complex.

This research also explored machine learning models that integrate urinary miRNA levels with patient clinical data to improve predictive power. Early results show that combining miRNA signatures with eGFR trends and immunosuppression levels enhances diagnostic accuracy to >90%.

Conclusion

Urinary exosomal microRNAs represent a promising class of non-invasive biomarkers for the early detection of acute kidney transplant rejection. Their ability to reflect allograft inflammation at the molecular level—before clinical or histological damage is evident—makes them powerful tools for personalized transplant monitoring. Continued refinement in isolation techniques, validation in larger cohorts, and integration with clinical decision support tools will be essential to bring these biomarkers from bench to bedside. Ultimately, miRNA-based diagnostics may reduce the need for invasive biopsies, enable proactive graft management, and improve long-term transplant outcomes.

References

1. Zieli艅ska K, Kukulski L, Wróbel M, Przyby艂owski P, Rokicka D, et al. (2022) Carbohydrate Metabolism Disorders in Relation to Cardiac Allograft Vasculopathy (CAV) Intensification in Heart Transplant Patients According to the Grading Scheme Developed by the International Society for Heart and Lung Transplantation (ISHLT). Ann Transplant 27: 933420.

   Indexed at, Google Scholar, Crossref

2. Raffa GM, Di Gesaro G, Sciacca S, Tuzzolino F, Turrisi M, et al. (2016) Heart transplant program at IRCCS-ISMETT: Impact of mechanical circulatory support on pre- and post -transplant survival. Int J Cardiol 219: 358-361.

   Indexed at, Google Scholar, Crossref

3. Kitamura S (2012) Heart transplantation in Japan: a critical appraisal for the results and future prospects. Gen Thorac Cardiovasc Surg 60: 639-644.

   Indexed at, Google Scholar, Crossref

4. Delgado JF, Reyne AG, de Dios S, López-Medrano F, Jurado A, et al. (2015) Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation. J Heart Lung Transplant 3:1112-1119.

   Indexed at, Google Scholar, Crossref

5. Wever-Pinzon O, Edwards LB, Taylor DO, Kfoury AG, Drakos SG, et al. (2017) Association of recipient age and causes of heart transplant mortality: Implications for personalization of post-transplant management-An analysis of the International Society for Heart and Lung Transplantation Registry. J Heart Lung Transplant 36: 407-417.

   Indexed at, Google Scholar, Crossref

6. Saczkowski R, Dacey C, Bernier PL (2010) Does ABO-incompatible and ABO-compatible neonatal heart transplant have equivalent survival. Interact Cardiovasc Thorac Surg 10: 1026-1033.

   Indexed at, Google Scholar, Crossref

7. Jeewa A, Manlhiot C, Kantor PF, Mital S, McCrindle BW, et al. (2014) Risk factors for mortality or delisting of patients from the pediatric heart transplant waiting list. J Thorac Cardiovasc Surg 147: 462-468.

   Indexed at, Google Scholar, Crossref

8. Conway J, Manlhiot C, Kirk R, Edwards LB, McCrindle BW, et al. Mortality and morbidity after retransplantation after primary heart transplant in childhood: an analysis from the registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 33: 241-251.

   Indexed at, Google Scholar, Crossref

9. R D Vanderlaan, C Manlhiot, L B Edwards, J Conway, B W McCrindle, et al. (2015) Risk factors for specific causes of death following pediatric heart transplant: An analysis of the registry of the International Society of Heart and Lung Transplantation. Pediatr Transplant 19: 896-905.

   Indexed at, Google Scholar, Crossref

10. Sivathasan C, Lim CP, Kerk KL, Sim DK, Mehra MR, et al. (2017) Mechanical circulatory support and heart transplantation in the Asia Pacific region. J Heart Lung Transplant 36: 13-18.

    Indexed at, Google Scholar, Crossref